| Similar Articles |
|---|
 |
CFO
March 1, 2008
Kate O'Sullivan |
As the World Churns Some of Corporate America's biggest names parted ways with their CFOs in the past year.   |
CFO
August 1, 2007
Kate Plourd |
Foreign Intrigue The mystery deepens at International Rectifier Corp... Former Biogen Idec CFO replaces legendary Merck CFO Judy C. Lewent, who is retiring... etc. |
BusinessWeek
September 20, 2004
Amy Barrett |
Merck: Who Will Revive The Giant? Earnings and new-drug disappointments have investors worried about succession. |
CFO
November 1, 2008
Alix Stuart |
Making the Leap There are many ways to get to the top spot in finance. |
CFO
June 1, 2007
Laura DeMars |
Not Cleared for Takeoff Controllers who want to become CFOs need to put down their pencils and master soft skills. |
The Motley Fool
January 25, 2006
Tim Hanson |
Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head. |
The Motley Fool
January 27, 2004
Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
Chemistry World
March 13, 2007 |
Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack. |
CFO
April 1, 2007
Laura DeMars |
The Tenure Track Amid rapid turnover in the ranks of chief financial officers, this trio of CFOs stayed in their posts longer than expected... Initially set up in 1999 to provide wealth-management services for multimillionaires, will MyCFO pass the smell test?... |
Pharmaceutical Executive
January 1, 2006
Jeannette Park |
Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future. |
The Motley Fool
July 23, 2004 |
The Mysterious CFO You'll hear about many CFOs as you read financial articles, but what exactly do CFOs do besides make occasional brief appearances? |
CFO
June 1, 2008
Alix Stuart |
Secrets of Their Success How the top women in finance staked their claims to the C-suite. |
CFO
November 1, 2009
Alix Stuart |
When CFOs Take the Top Spot It doesn't happen often, but when CFOs become CEOs, companies often outperform, at least on stock prices. |
BusinessWeek
September 5, 2005
Amy Barrett |
The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come |
BusinessWeek
July 25, 2005
Gene G. Marcial |
Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion. |
Bio-IT World
December 15, 2004
Kevin Davies |
Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first. |
The Motley Fool
September 30, 2004
W. D. Crotty |
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. |
The Motley Fool
October 23, 2006
Brian Lawler |
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. |
The Motley Fool
October 21, 2004
Brian Gorman |
Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight. |
CFO
May 8, 2006
Don Durfee |
What's the Boss Worth? CFOs weigh in on executive compensation. |
CFO
September 1, 2005 |
Short Shift Are companies hurting their chances for success by rearranging the executive suite so often?... Accounting has been a struggle at the Department of Homeland Security.... |
CFO
June 1, 2006
Alix Nyberg Stuart |
What Women Want In finance, the operative words are opportunity, flexibility, and balance. As they approach the top position -- CFO, the pull between work and life seems to tug harder at women than at men. |
CFO
April 1, 2006
Kate O'Sullivan |
Calming the Waters What happens when the CEO and CFO just don't get along? And what should CFOs do when they find themselves locking horns with their boss? |
The Motley Fool
January 31, 2007
Brian Lawler |
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. |
CFO
May 1, 2004 |
Nortel Disconnect Frank Dunn Under the Gun... The Good Life... CFOs on the Move... |
BusinessWeek
April 21, 2011
Tom Randall |
Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines. |
CFO
April 1, 2007
Joseph McCafferty |
Business Outlook Survey With renewed confidence in the economy, companies report that they are investing in their businesses -- ramping up hiring plans and increasing projections for capital spending. |
CFO
November 1, 2009
Kate O'Sullivan |
After the Storm What impact will the recession have on your career prospects? |
CFO
December 1, 2003
Kate O'Sullivan |
Embracing Change There is an upside to the high CFO turnover rate these days: lots more opportunities for those looking to make a move. |
CFO
March 1, 2007
Joseph McCafferty |
For CFOs, Few Gold Watches The average tenure of big-company finance chiefs is less than five years, according to a recent study. |
CFO
March 1, 2010
Kate O'Sullivan |
Lords of the Brass Ring The time may be right for financial chiefs to ascend to the CEO post. |
The Motley Fool
January 25, 2005
Stephen D. Simpson |
Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today. |
CFO
February 1, 2009
Scott Leibs |
Moving On, Happily Most CFOs leave their jobs in triumph, not disgrace, a new KPMG study shows. |
The Motley Fool
September 25, 2006
Brian Lawler |
Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note. |
CFO
November 1, 2003
David M. Katz |
The Price They're Paid Even without stock options, top finance chiefs are changing in hefty pay packages. |
CFO
September 1, 2006
Kate O'Sullivan |
Private Club Opportunity is knocking for CFOs who have the skills that private-equity firms demand. |
CFO
February 1, 2008
Roy Harris |
Are We Strategic Yet? Early in a CFO's tenure, the things that matter most often get the least attention. |
CFO
October 1, 2008
Alix Stuart |
A Chicken and Nest-Egg Problem Persuading employees to participate in company retirement plans isn't getting any easier. |
Fast Company
March 2004
Jennifer Reingold |
CEO See-Ya! Raymond Gilmartin, CEO of Merck & Co. gets the ax. |
CFO
Kris Frieswick |
Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist... |
CFO
June 1, 2005 |
Throwing In the Towel Outback's CFO is mad as hell... A rogue trader's new job... CFOs on the move... |
CFO
July 15, 2009
Kate O'Sullivan |
Power Struggle Will the recession short-circuit women's advancement to the top spots in finance? |
CFO
December 1, 2008
Kate Plourd |
Bad News Bearers Why CFOs should learn the fine art of delivering inconvenient truths. |
BusinessWeek
March 6, 2006
Amy Barrett |
Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster. |
The Motley Fool
February 21, 2006
Rick Aristotle Munarriz |
Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes. |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here. |
The Motley Fool
August 26, 2005
Stephen D. Simpson |
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. |
CFO
November 1, 2007
Alix Stuart |
The Essential Skills To ascend to (and remain in) the CFO's office, you need much more than financial acumen. |
CFO
September 1, 2007
Laura DeMars |
Vice Can Be Nice Companies offer the vice-chair post to CFOs and ex-CFOs as everything from a consolation prize to preparation for the CEO job. |
The Motley Fool
January 31, 2005
Stephen D. Simpson |
Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break. |
